Clinical trial

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

NCT02195232

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-01-01

PhasePHASE2 / PHASE3

Study timeline

Study start (actual)2015-01-01Date precision: month

Registry last updated2021-03-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Thromboembolism of Vein VTE in Colorectal Cancerunresolved

Thromboembolism of Vein in Pancreatic Cancerunresolved

Thromboembolism of Vein in Non-small Cell Lung Cancerunresolved

Interventions

IsoquercetinDRUG

Sponsors & collaborators

Jeffrey Zwicker, MDlead sponsor

Quercegen Pharmaceuticalscollaborator

National Heart, Lung, and Blood Institute (NHLBI)collaborator

Mapped research locations

BostonMassachusetts, United States2 Los AngelesCalifornia, United States1 St LouisMissouri, United States1 Washington D.C.District of Columbia, United States1 SacramentoCalifornia, United States1 ProvidenceRhode Island, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02195232 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.